Concepedia

Julius Kirui

JK

Statistics

Publications

3

Citations

53

H-Index

3

Active since

2020

Affiliations

Sarah Cannon(Current)

Tennessee Oncology

Daiichi Sankyo (United States)

University of Oklahoma

Julius Kirui is an author at Sarah Cannon specializing in tumor biology, medicine, and oncology.

Top concepts

Publications per year

2020–2022

3

Publications

3

Phase I, two-part, multicenter, first-in-human (FIH) study of DS-6000a in subjects with advanced renal cell carcinoma (RCC) and ovarian tumors (OVC).

Erika Hamilton, Shekeab Jauhari, Kathleen N. Moore et al. · Journal of Clinical Oncology · 2022 · 19 citations

, , +22

DS-7300 (B7-H3 DXd-ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A subgroup analysis of a phase 1/2 multicenter study.

Manish R. Patel, Melissa L. Johnson, Gerald S. Falchook et al. · Journal of Clinical Oncology · 2022 · 18 citations

, , +25

BT5528-100 phase I/II study of the safety, pharmacokinetics, and preliminary clinical activity of BT5528 in patients with advanced malignancies associated with EphA2 expression.

Johanna C. Bendell, Judy Sing-Zan Wang, Babar Bashir et al. · Journal of Clinical Oncology · 2020 · 16 citations

, , +19

1–3 of 3